AbbVie — Third Quarter 2026 Earnings Summary

AbbVie reported third-quarter 2026 net revenues of $17.404 billion, representing a 10.3% increase on a reported basis, driven primarily by strong growth in its immunology and neuroscience portfolios. The company achieved diluted earnings per share of $2.37 on a GAAP basis and $3.82 on an adjusted basis, while raising its full-year adjusted EPS guidance to a range of $13.95 to $13.99. Key product performance included Skyrizi revenues of $5.776 billion and Rinvoq revenues of $2.706 billion, which offset declines in Humira sales. Additionally, AbbVie completed its acquisition of Apogee Therapeutics to expand its immunology pipeline and announced a 5.2% increase in its quarterly dividend payable in February 2027.